MDGN News Alert Medgenics Inc. Common Stock (MDGN) 7.13 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 1:37 AM

Medgenics Inc. Common Stock (MDGN) 7.13 $MDGN

Medgenics' (MDGN) CEO Mike Cola on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 13, 1:26PM CST

MDGN: 7.13 (-0.75)

Medgenics FY14 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:29AM CST

MDGN: 7.13 (-0.75)

Medgenics reports Q4 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:05AM CST

MDGN: 7.13 (-0.75)

Medgenics to Host Conference Call to Announce Fourth Quarter and Full Year 2014 Results on February 13, 2015
GlobeNewswire - Fri Jan 30, 7:36AM CST
Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Friday, February 13, 2015 at 8:30 a.m. ET to discuss fourth quarter and full year 2014 financial results.
MDGN: 7.13 (-0.75)

Should You Purchase Medgenics After Its Recent Run Up?
Diamond Technology Management - at Seeking Alpha - Wed Jan 28, 11:13AM CST

MDGN: 7.13 (-0.75)

Medgenics to Present at Biotech Showcase 2015 Conference
GlobeNewswire - Thu Jan 08, 7:50AM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at the Biotech Showcase 2015 Conference in San Francisco, CA.
MDGN: 7.13 (-0.75)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 4:36PM CST

RICE: 19.13 (-0.22), FRPT: 16.78 (-0.12), KGC: 2.81 (-0.17), AUQ: 3.58 (-0.03), MDGN: 7.13 (-0.75), JNUG: 30.90 (+1.14), FOMX: 9.01 (-0.03), MRD: 18.66 (+0.23), KOS: 9.05 (+0.10), YUM: 74.69 (-0.11)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:45AM CST

LGCY: 13.35 (+0.51), PFIE: 2.60 (-0.06), MCEP: 6.29 (+0.12), MDGN: 7.13 (-0.75), LQDT: 9.52 (+0.09), AXPW: 0.39 (-0.04), PRTK: 26.95 (+0.65), BSI: 2.97 (+0.02), DRIV: 25.99 (+0.06), CBST: 101.94 (+0.14), QTWW: 2.96 (-0.04), CALA: 16.11 (+0.62), MPO: 1.00 (-0.02), SNSS: 2.28 (+0.01), CTP: 6.53 (+0.13), LPX: 17.44 (+0.42), SAEX: 3.75 (+0.50), DRYS: 1.01 (+0.02), VPCO: 1.02 (+0.01), XLRN: 38.02 (+0.07)

InsiderInsights.com Daily Round Up 12/2/14: CINF, MDGN, AVID, NHF
InsiderInsights - at Seeking Alpha - Wed Dec 03, 6:11PM CST

BTF: 27.69 (-0.13), A: 40.15 (+0.13), MDGN: 7.13 (-0.75), NU: 51.02 (-1.28), BBY: 39.11 (-0.08), SPB: 94.05 (+0.80), MAR: 79.39 (+0.37), AVID: 14.12 (+0.34), CINF: 52.46 (+0.27), MPC: 103.48 (+2.08), NHF: 11.69 (+0.08), EPM: 6.70 (+0.07), EMC: 27.99 (+0.12), DNY: 21.99 (-0.01), MC: 30.79 (+0.52), TWI: 9.63 (+0.04), SFXE: 3.49 (+0.01), CSCO: 29.43 (-0.03)

Medgenics Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock
GlobeNewswire - Mon Dec 01, 3:02PM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and the patient's own tissue for the treatment of rare and orphan diseases, today announced the completion of an underwritten public offering of 5,893,750 shares of its common stock, including 768,750 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Medgenics at a price to the public of $4.10 per share. The gross proceeds from this offering to Medgenics were approximately $24.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Medgenics.
MDGN: 7.13 (-0.75)

Medgenics proposes public offering of common shares
M2 - Wed Nov 26, 6:59AM CST
Gene therapy platform Medgenics (NYSE MKT:MDGN) said on Tuesday that it plans to offer and sell shares of its common stock in an underwritten public offering.
MDGN: 7.13 (-0.75)

Medgenics to Present at 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:01PM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will participate in a fireside chat discussion at the 26 Annual Piper Jaffray Healthcare Conference in New York.
MDGN: 7.13 (-0.75)

Medgenics prices offering
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 8:41AM CST

MDGN: 7.13 (-0.75)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 8:15AM CST

SCOK: 2.83 (-0.18), CAMT: 3.08 (+0.09), NUAN: 14.26 (+0.20), MDGN: 7.13 (-0.75), PHMD: 1.68 (+0.04), ISNS: 2.49 (+0.03), AVG: 20.73 (+0.25), LIVE: 3.23 (-0.22), RVLT: 1.14 (-0.02), DSKY: 11.99 (+0.14), DSW: 36.59 (+0.15), QIHU: 60.48 (+1.47), PBR: 6.98 (+0.44), WDAY: 91.84 (+0.67), LAKE: 10.18 (+0.89)

Medgenics Prices Public Offering of Common Stock
GlobeNewswire - Tue Nov 25, 8:07AM CST
Medgenics, Inc. (NYSE MKT:MDGN) today announced the pricing of 5,125,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $4.10 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 768,750 shares of its common stock. Gross proceeds to Medgenics from the sale of shares are expected to be approximately $21.0 million, excluding any exercise of the underwriters' option to purchase additional shares of common stock. If the underwriters' option is exercised in full, gross proceeds will be $24.2 million. The offering is expected to close on or about December 1, 2014 subject to customary closing conditions.
MDGN: 7.13 (-0.75)

Medgenics Announces Public Offering of Common Stock
GlobeNewswire - Mon Nov 24, 3:01PM CST
Medgenics, Inc. (NYSE MKT:MDGN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. As part of this proposed offering, Medgenics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public. Medgenics has developed a proprietary ex vivo gene therapy platform for the sustained production and delivery of therapeutic proteins and peptides using a patient's own tissue. The company focuses on rare and orphan diseases.
MDGN: 7.13 (-0.75)

Medgenics Announces Rare & Orphan Disease Research Collaboration With The Children's Hospital of Philadelphia
GlobeNewswire - Wed Nov 12, 3:02PM CST
-- Collaboration will bring together the premier pediatric genomics research organization, Center for Applied Genomics (CAG), with ex vivo gene therapy innovator, Medgenics, to discover and accelerate the development of new therapies for rare and orphan diseases.
MDGN: 7.13 (-0.75)

New Positive Clinical Data Supports Quest Towards Orphan Designations
Brian Marckx, CFA - at Seeking Alpha - Fri Oct 17, 5:45AM CDT

JNJ: 99.62 (+1.18), MDGN: 7.13 (-0.75), AMGN: 153.48 (+0.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

AEVEX Facing Class Action: Deadline Looms for Investors

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Cancer Memoir Shows Healing Beyond Medicine

Confronting the Unfathomable Out of the North Carolina mountains comes a story that defies expectations—a pastor and farmer named Mark Heisey, who faced the no-holds-barred trials of stage IV-B lymphoma. Now, I'll shoot you straight: this isn't your run-of-the-mill self-help guide or a clinical breakdown of battling cancer. His new memoir dives into the personal and...

TomoIQ Unveils Money Finder at Money20/20 Event

Breaking Down Financial Barriers with AI In the hustle of Money20/20 USA in Las Vegas, TomoIQ dropped a financial bombshell with their latest tool, Money Finder. This isn't just another app in the sea of fintech solutions. Nope, this one promises to cut through the complexities that most folks face when trying to get their financial house in order. An AI Buddy for...

2GenPen & LordCap Team Up: Game-Changer in ABS?

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Chicago Scenic Studios’ Equipment Up for Grabs in Auction

A Peek into the Sale: What's on the Block? Get that coffee brewing and settle in, because we've got to unpack some interesting stuff happening with Chicago Scenic Studios. This isn't just any Craigslist decampment—Integra Asset Solutions is rolling out an online auction come October 27 that’ll have equipment-savvy investors’ ears perking up like they just snagged a...